84 - Oral Communication
Diagnostic laboratory: Today & tomorrow
Feb. 26, 2021, 1:45 p.m. - 3:15 p.m., Sydney


Application of the STG-Bleedscreen assay in clinical routine
T. Siegemund, A. Siegemund, H. Bönigk, Presenter: T. Siegemund (Magdeburg)

Background and Objective
Multiple defects can cause a bleeding diathesis. But often a single factor level is not sufficient to predict the bleeding tendency of the affected patient. Global assays, like the fully automated STG-Bleedscreen, may be better predictors of bleeding events and may help to tailor treatment.
Since January 2020 all patients with suspected or confirmed bleeding diathesis in our center were include in this study (with informed consent). A total of 520 measurements were performed using STG-Bleedscreen on the ST Genesia analyzer (Stago). This includes 64 measurements in samples from patients with hemophilia A, and 19 samples with hemophilia B. Results are expressed as thrombin peak in nanomolar concentration, and normalized with a standard plasma (in %).
In average, patients with suspected bleeding diathesis (no hemophilia) showed a normal thrombin generation of 160 ± 100 nM (normalized 107 ± 50 %). Nevertheless, patients with blood type O show significantly reduced thrombin generation accompanied with lower levels of FVIII and VWF. Patients with hemophilia showed similar reduction of thrombin generation: 51 ± 35 nM or 36 ± 23 % for hemophilia A and 46 ± 13 nM or 31 ± 9 % for hemophilia B. The assay shows a good correlation between factor VIII level and thrombin peak, not enough data could be collected in hemophilia B. In patients receiving products with enhanced half-life, thrombin generation clearly shows the prolonged protective effect.
The STG-Bleedscreen assay is useful in monitoring hemophilia and hemophilia treatment. Especially, the assay shows the prolonged activity of enhanced half-life products. In patients with suspected bleeding diathesis, the assay might be able to separate patients with a defect in the plasmatic coagulation system, platelets are not included in the assay. The STG-Bleedscreen assay is a fully automated assay. It can be easily implemented in daily routine, as it does not require high technical effort. The STG-Bleedscreen shows a similar behavior compared to the manual CAT method.
Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.